Zhejiang Medicine announces share repurchase plan via centralized bidding

Zhejiang Medicine Co., Ltd. (SSE:600216) announced a share repurchase plan to acquire the company's own shares through centralized bidding transactions. The repurchase is intended for use in employee stock ownership plans or equity incentives to improve investor confidence. The total repurchase amount will range from CNY 100 million to CNY 200 million. The repurchase price will not exceed CNY 20.83 per share. The funds will come from the company's own funds or self-raised funds. The repurchase period will run from April 15, 2025, to April 14, 2026. Guotou High-Tech, a shareholder holding more than 5% of shares, has previously disclosed a plan to reduce its holdings, which is still ongoing and may affect the repurchase progress. The plan is subject to market conditions and regulatory requirements.